Recommendations for the prevention and management of tuberculosis in patients taking infliximab.
An unusually large number of cases of tuberculosis, often with miliary or widespread dissemination, has been reported in patients taking infliximab for rheumatoid arthritis or Crohn's disease. Recommendations have been issued in France regarding the definition of high-risk patients, the screening methods to be used in these patients, and possible prophylactic treatments. The present update is also intended to help physicians manage tuberculosis occurring before or during infliximab therapy.
Salmon-Ceron
Dominique
D
Service de Médecine Interne, Hôpital Cochin, Paris. dominique.salmon@cfx.ap-hop-paris.fr
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D003424:Crohn Disease / Q000188:drug therapy; D004359:Drug Therapy, Combination; D005602:France; D006801:Humans; D016867:Immunocompromised Host; D000069285:Infliximab; D014376:Tuberculosis / Q000139:chemically induced* / Q000188:drug therapy
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000995:Antitubercular Agents; D000069285:Infliximab